Long-term prognosis and overall mortality in patients with progressive multifocal leukoencephalopathy

Sci Rep. 2023 Aug 31;13(1):14291. doi: 10.1038/s41598-023-41147-9.

Abstract

Progressive multifocal leukoencephalopathy (PML) is a rare but fatal opportunistic infection and mainly occurs in patients with immunosuppressive conditions. Despite the increasing number of patients receiving immunosuppressive treatments, studies on PML are still lacking due to its low prevalence and incidence. We retrospectively reviewed patients diagnosed with PML in two tertiary hospitals in South Korea from 1999 to 2021. Total of 47 PML patients were included. Of 27 patients (57.4%) were diagnosed with human immunodeficiency virus (HIV). Median last follow-up modified Rankin Scale (mRS) score was higher in the non-HIV PML group than that in the HIV group (5 vs. 4, p = 0.020). Median survival duration was lower in the non-HIV group (184 vs. 1,564 days). The 1-year and overall mortality rates of PML patients were significantly higher in the non-HIV group than that in HIV group (60.0% vs. 25.9%, p = 0.019; 80.0% vs. 40.7%, p = 0.007). Initial mRS score (HR 1.685, p = 0.038) and highly active antiretroviral therapy (HAART) in HIV patients (HR 0.374, p = 0.013) had a significant effect on overall mortality. Our findings suggest that early detection of PML with low mRS score and early initiation of HAART in patients with HIV may improve prognosis.

MeSH terms

  • Antiretroviral Therapy, Highly Active
  • HIV Infections* / complications
  • Humans
  • Immunosuppressive Agents
  • Leukoencephalopathy, Progressive Multifocal* / diagnosis
  • Prognosis
  • Retrospective Studies

Substances

  • Immunosuppressive Agents